Black Rose IndusQ3 FY24

Black Rose Indus Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹106.74P/E: 15.7Market Cap: ₹544 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • Acrylamide solid export volumes expected to increase this quarter due to new customer acquisition and better product acceptance despite global market disruptions (Page 17).
  • Polyacrylamide liquid sales affected by subdued demand in Morbi tile industry but new R&D efforts on improved binders and dispersants aim to boost revenue and product mix (Page 5).
  • NMA (N-Methyl Acetoacetamide) commercial sales started with a large customer, expected to raise revenue and profit substantially (Page 5).
  • Distribution business anticipates substantial volume and revenue growth supported by stable domestic demand, improved supply from principals, and expected export volume pick-up after US demand revival (Page 4).
  • Manufacturing volumes largely flat quarter-to-quarter, but 9 months show slight growth with expectation to surpass previous fiscal year volumes (Page 15).
  • At full capacity and current market conditions, manufacturing revenue potential estimated between ₹300 to ₹400 crores (Page 14).
  • Overall focus remains on maximizing sales, revenue, and profitability aligned with competitive pricing and cost efficiencies (Pages 14-17).

See what Black Rose Indus management said on margin guidance — free account, 30 seconds.

Fundraise plans

- The company has not indicated any immediate plans to raise funds currently. - Mentioned that once technology and processes for new projects are finalized, they will consider fundraising options at the appropriate time. - Specifically, for the polyacrylamide solid plant, an investment of ₹60 to ₹100 crores is anticipated depending on the technology chosen. - The mode of raising this capital (debt/equity) will be decided when implementation starts. - Management emphasized no current need to raise funds or dilute equity. - Any future fundraising will be aligned with project requirements and finalized plans. In summary, no current fundraising is underway, but future fundraising may occur based on technology finalization and project commencement.

See what Black Rose Indus management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Black Rose Industries is planning a polyacrylamide solid plant requiring an investment between ₹60 to ₹100 crore, depending on the technology chosen (domestic or imported).
  • The company is in advanced discussions for a specialty chemicals project at the Jhagadia site in collaboration with a Japanese principal.
  • Talks are underway for two toll manufacturing projects related to acrylamide chemistry with companies from Europe and the US.
  • The company is also seeking to acquire about 20 acres of new land for future projects and expansion requirements.
  • Fund-raising for these investments will be considered at the appropriate time after finalizing the technology and project details.
  • Current capital expenditure on existing capacity setups (like NMA and acrylamide solid) has been very low, benefiting from low CapEx structures.

Track Black Rose Indus — get its next earnings analysis in your feed

How does Black Rose Indus rank vs peers in Chemicals & Petrochemicals?

Pro feature
ThisBlack Rose Indus
Rev 3Mar 3

How does Black Rose Indus rank in Chemicals & Petrochemicals?

Compare Black Rose Indus against every Chemicals & Petrochemicals company (Q3 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Others in Chemicals & Petrochemicals this season

  • Seya Industries (Q2 FY27)

    Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's

  • DCM Shriram Fine Chemicals (Q2 FY27)

    9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri

  • Dhariwalcorp (Q2 FY27)

    For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…

  • Agastya Energy (Q2 FY27)

    For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →